SCAPHO 150MG

Description

Scapho 150mg is a Subcutaneous IgG1 monoclonal antibody which prevents interleukin-17A (IL-17A) by binding to its receptor; maintenance dose given once monthly
Used for curing adults with moderate to severe plaque psoriasis, psoriatic arthritis (PsA), and ankylosing spondylitis; in PsA, the drug slows progression of joint damage
May have high risk for severe infection and may leads to hypersensitivity reactions

Indication

Scapho 150mg indicated for the treatment of patients with following condition;

Plaque Psoriasis

Psoriatic arthritis

Ankylosing spondylitis

Dosage and administration

Plaque Psoriasis

Starting dose: given 300 mg SC at weeks 0, 1, 2, 3, and 4

 initially at week 8, administer 300 mg SC once monthly

 The recommended dose of 150 mg may be acceptable for some patients

Psoriatic Arthritis

Indicated for adults with active psoriatic arthritis

 Recommended dosage

 Psoriatic arthritis for other patients, administer with or without a loading dosage by SC injection

 Scapho with loading dose administrated 150 mg SC at weeks 0, 1, 2, 3, and 4 and q4wk thereafter

 Scapho without loading dose administrated 150 mg SC q4wk.

 Consider a dosage of 300 mg, If a patient continues to have active psoriatic arthritis

 May be administered with or without methotrexate.

Ankylosing Spondylitis

Given with or without a loading dosage by SC injection

 Scapho with loading dose is administrated 150 mg SC at weeks 0, 1, 2, 3, and 4 and q4wk thereafter

 Scapho without a loading dose is administrated150 mg SC q4wk

 Mechanism of action

Secukinumab belongs to human IgG1 monoclonal antibody whichspecially binds to the interleukin-17A (IL-17A) cytokine, preventing its combining with the IL-17 receptor. A naturally occurring cytokine, IL-17A is contains in normal inflammatory and immune responses. IL-17A activates keratinocytes to secrete chemokines and other proinflammatory cells. Increase concentrations of IL-17A are found in psoriatic plaques. Secukinumab treatmentprohibits the release of proinflammatory cytokines and chemokines and may decrease epidermal neutrophils and IL-17A concentrations in psoriatic plaques.

ADME Properties

Absorption: peak plasma concentration for single dose is 6 days and weekly dosing for first month is 31-34 days

Distribution: volume of distribution is 7.1 – 8.6 (IV administration)

Metabolism: Metabolized via intracellular catabolism

Elimination: half-life is 22-31 days

Side effects

infections

Nasopharyngitis

Diarrhea

URT infection

Rhinitis

Oral herpes

Pharyngitis

Urticaria

Rhinorrhoea

 Drug interaction

CYP450 substrates interaction with scapho injection may altered by increased levels of certain cytokines

Live vaccinations interaction with scapho should be avoided

Contraindication

Patients having Serious hypersensitivity reactions to the active substance or to any of the excipients

Precautions

• Scapho may have increased risk of infections; use with caution in patients with chronic infection or a history of recurrent infection
• May infuriate Crohn disease
• Anaphylaxis and cases of urticaria resulted; if this appears, discontinue scapho immediately and start anaphylaxis treatment
• The treatment initiated with anti-TB therapy before to initiation of scapho in patients with a history of latent or active TB in whom an adequate course of treatment cannot be confirmed

Pregnancy

Pregnancy category is B

Use the Scapho 150mg with caution during pregnancy

Lactation

Excretion into human milk is unknown

Storage

Store the drug at 2⁰C – 8⁰C

Store in original carton and protect from light until the time of use

Missed dose

If missed dose occurs, patients must consult with medical practitioner and follow the instructions given by them.

Or missed dose should be avoid and follow the regular dosing schedule.